Troubled KV emerges from bankruptcy; Report: Biotechs shoulder the load on antibiotic R&D;

@FierceBiotech: Veeva, provider of sales software to Merck, seeks up to $150M in IPO. Story from FierceBiotech IT | Follow @FierceBiotech

@JohnCFierce: ICYMI: ViroPharma shares soar on report of possible buyout offer. Article | Follow @JohnCFierce

@EmilyMFierce: Cheaper sequencing points cancer drug researchers to 'super responders.' More | Follow @EmilyMFierce

> After getting pummeled by compounding pharmacies in a showdown over its new drug to prevent premature labor, KV Pharmaceuticals ($KV.A) has emerged from Chapter 11 bankruptcy with a recapitalization of $375 million in new credit and a rights offering. Release

BioWorld covers the antibiotics R&D work underway at biotechs in the wake of Big Pharma's big exit from the field. Story

Medical Device News

@FierceMedDev: Foundation Medicine eyes $92M in IPO. ICYMI Friday | Follow @FierceMedDev

@DamianFierce: Columbia Labs is buying into the CRO biz for $25M, grabbing Molecular Profiles. More from FierceCRO | Follow @DamianFierce

@MarkHFierce: Touch may help prevent hacking of insulin pumps and other wireless, implanted devices. Article via MIT Technology Review. | Follow @MarkHFierce

@MichaelGFierce: Delcath's chemo delivery device suffers FDA rejection. ICYMI from FierceDrugDelivery | Follow @MichaelGFierce

> Quidel scores FDA nods for Life Tech-powered tests. News

> Bard resolves New Jersey vaginal mesh suit. Report

> NeoTract's enlarged prostate implant gains FDA de novo nod. Story

Pharma News

@FiercePharma: GSK's happy: Arzerra won FDA breakthrough status; now, priority review for melanoma combo Tafinlar + Mekinist. Article | Follow @FiercePharma

@EricPFierce: GSK, Genmab get FDA 'breakthrough' designation for Arzerra in first-line use. ICYMI Friday | Follow @EricPFierce

@CarlyHFierce: Check out the new report by @EricPFierce: Top 10 rheumatoid arthritis drugs 2013. Feature Follow @CarlyHFierce

> Roche lands Lufthansa CEO to take over chairman's job. News

> New Ranbaxy import ban provides Novartis with unexpected benefit. Story

> Viehbacher: Sanofi's options include buying back stake from L'Oreal, upping stake in Regeneron. Article

CRO News

> Harlan ups its European presence. Item

> Theorem teams with Charles River on preclinical work. Report

> Indian CRO TCG teams with Debiopharm for antibiotics. More

> Bayer taps DKSH with eye on Singapore. Story

> Italy's CROS NT reaches into U.S. with Stat-Tech buyout. Article

Biotech IT News

> TranSMART releases new version of research software from Johnson & Johnson. Item

> Qlucore corrals EU funding for hepatitis C software. Report

> AstraZeneca supports iPhone app for helping patients with heart disease. Article

> MIT center grabs $25M grant to build human-like computers. More

> Treato releases latest software: not another social media-listening app for pharma? Story

And Finally… Obesity damages the way your stomach sends signals about whether it's full or not. And researchers say that losing weight doesn't fix your body's signaling mechanism. Release

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.